T. K. Harden

发表

Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3',5'-monophosphate (cGMP).

R. Mailman, G. Breese, M. Ondrušek, 1978, Life sciences.

Overview of the Alliance for Cellular Signaling

Temple F. Smith, D. Botstein, A. Arkin, 2002, Nature.

Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.

S. Moro, K. Jacobson, T. K. Harden, 1998, Journal of medicinal chemistry.

Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands.

S. Moro, K. Jacobson, P. Herdewijn, 2000, Journal of medicinal chemistry.

Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.

K. Jacobson, T. K. Harden, J. Boyer, 2001, Journal of medicinal chemistry.

Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.

K. Jacobson, T. K. Harden, M. González-Moa, 2005, Journal of medicinal chemistry.

Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors.

K. Jacobson, Zhang-Guo Gao, T. K. Harden, 2006, Biochemical pharmacology.

P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring.

K. Jacobson, T. K. Harden, I. Tikhonova, 2007, Journal of medicinal chemistry.

Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.

Jacobson, K. Jacobson, T. K. Harden, 2011, Journal of medicinal chemistry.

Exploring a 2-Naphthoic Acid Template for the Structure-Based Design of P2Y14 Receptor Antagonist Molecular Probes

Kyle A. Brown, R. Stevens, K. Jacobson, 2014, ACS chemical biology.

Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists

Kyle A. Brown, K. Jacobson, T. K. Harden, 2016, Journal of medicinal chemistry.

Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules.

T Kendall Harden, Richard C Boucher, T. K. Harden, 2003, Molecular pharmacology.

Dual Activation of Phospholipase C-ϵ by Rho and Ras GTPases*

Stephanie N. Hicks, John Sondek, T. Kendall Harden, 2008, Journal of Biological Chemistry.

Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes.

P. Hawkins, L. Stephens, T. K. Harden, 1988, The Biochemical journal.

A comparison of calcium-activated potassium channel currents in cell- attached and excised patches

T. K. Harden, J. Hepler, T K Harden, 1987, The Journal of general physiology.

The Pleckstrin Homology Domain of Phospholipase C-β2 as an Effector Site for Rac*

T. K. Harden, J. Sondek, M. Wing, 2003, Journal of Biological Chemistry.

Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process.

T. K. Harden, J. Perkins, Y. Su, 1980, The Journal of biological chemistry.

Recovery of beta-adrenergic receptors following long term exposure of astrocytoma cells to catecholamine. Role of protein synthesis.

T. K. Harden, J. Perkins, R. Doss, 1981, The Journal of biological chemistry.

Expression of a cloned P2Y purinergic receptor that couples to phospholipase C.

T. K. Harden, T. Filtz, J. Boyer, 1994, Molecular pharmacology.

Structure activity relationships for derivatives of adenosine‐5′‐triphosphate as agonists at P2 purinoceptors: Heterogeneity within P2x and P2y subtypes

G. Burnstock, K. Jacobson, T. K. Harden, 1994 .

Synthesis of Extended Uridine Phosphonates Derived from an Allosteric P2Y2 Receptor Ligand

Kyle A. Brown, S. van Calenbergh, T. K. Harden, 2014, Molecules.

[32P]2‐iodo‐N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors

K. Jacobson, T. K. Harden, M. Ohno, 2006, British journal of pharmacology.

beta-adrenergic receptors in rat liver: effects of adrenalectomy.

P. Molinoff, T. K. Harden, B. Wolfe, 1976, Proceedings of the National Academy of Sciences of the United States of America.

In vitro study of beta-adrenergic receptors.

P. Molinoff, T. K. Harden, B. Wolfe, 1977, Annual review of pharmacology and toxicology.

Guanine nucleotides modulate the affinity of antagonists at beta-adrenergic receptors.

T. K. Harden, B. Wolfe, T. Harden, 1981, Journal of cyclic nucleotide research.

Rapid down regulation of beta adrenergic receptors by combining antidepressant drugs with forced swim: a model of antidepressant-induced neural adaptation.

G. Breese, T. K. Harden, R. Mueller, 1985, The Journal of pharmacology and experimental therapeutics.

Structural basis for the activation of PLC-γ isozymes by phosphorylation and cancer-associated mutations

T. K. Harden, J. Sondek, Qisheng Zhang, 2019, eLife.

Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.

K. Jacobson, T. K. Harden, P. Kováč, 2009, Bioorganic & medicinal chemistry.

Development of selective agonists and antagonists of P2Y receptors

K. Jacobson, T. K. Harden, S. de Castro, 2008, Purinergic Signalling.

Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.

T Kendall Harden, Stefano Costanzi, Piet Herdewijn, 2004, Bioorganic & medicinal chemistry.

Kinetics of activation of phospholipase C by P2Y purinergic receptor agonists and guanine nucleotides.

T. K. Harden, C. Downes, J. Boyer, 1989, The Journal of biological chemistry.

Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.

K. Jacobson, P. Herdewijn, T. K. Harden, 1999, Journal of medicinal chemistry.

2‐Chloro N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate is a selective high affinity P2Y1 receptor antagonist

K. Jacobson, T. K. Harden, J. Boyer, 2002 .

Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

K. Jacobson, T. K. Harden, X. Ji, 2002, Molecular pharmacology.

Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.

K. Jacobson, T. K. Harden, J. Boyer, 2002, Journal of medicinal chemistry.

Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.

K. Jacobson, Hak-Sung Kim, T. K. Harden, 2002, Journal of medicinal chemistry.

Ontogeny of β-adrenergic receptors in rat cerebral cortex

P. Molinoff, T. K. Harden, J. Perkins, 1977, Brain Research.

RGS6, RGS7, RGS9, and RGS11 Stimulate GTPase Activity of Gi Family G-proteins with Differential Selectivity and Maximal Activity*

T. K. Harden, E. Bodor, S. Hooks, 2003, The Journal of Biological Chemistry.

Crystal structure of the multifunctional Gβ5–RGS9 complex

T. K. Harden, J. Sondek, D. Siderovski, 2008, Nature Structural &Molecular Biology.

High-affinity binding of agonists to beta-adrenergic receptors on intact cells.

T. K. Harden, J. Perkins, M. Toews, 1983, Proceedings of the National Academy of Sciences of the United States of America.

DLC‐1 suppresses non‐small cell lung cancer growth and invasion by RhoGAP‐dependent and independent mechanisms

K. Hahn, C. Der, Y. Bang, 2008, Molecular carcinogenesis.

A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose–Stimulated Chemotaxis of Human Neutrophils

K. Jacobson, T. K. Harden, E. Lazarowski, 2013, Molecular Pharmacology.

Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([(125)I]MRS2500).

K. Jacobson, T. K. Harden, C. Gachet, 2010, Pharmacological research.

A fusion protein of the human P2Y(1) receptor and NTPDase1 exhibits functional activities of the native receptor and ectoenzyme and reduced signaling responses to endogenously released nucleotides.

T. K. Harden, J. Boyer, J. Mateo, 2002, Molecular pharmacology.

Structure of Gαi1 Bound to a GDP-Selective Peptide Provides Insight into Guanine Nucleotide Exchange

T. K. Harden, J. Sondek, D. Siderovski, 2005 .

A unique fold of phospholipase C-beta mediates dimerization and interaction with G alpha q.

T. K. Harden, J. Sondek, A. Singer, 2002, Nature structural biology.

Activation of phospholipase C-epsilon by heterotrimeric G protein betagamma-subunits.

C. Der, T. K. Harden, M. Wing, 2001, The Journal of biological chemistry.

Purification of an AlF4- and G-protein beta gamma-subunit-regulated phospholipase C-activating protein.

T. K. Harden, A. Morris, J. Boyer, 1991, The Journal of biological chemistry.

RhoA Activates Purified Phospholipase C-ϵ by a Guanine Nucleotide-dependent Mechanism*

T. K. Harden, J. Sondek, M. Wing, 2004, Journal of Biological Chemistry.

Application of RGS box proteins to evaluate G-protein selectivity in receptor-promoted signaling.

T. K. Harden, D. Siderovski, M. Hains, 2004, Methods in enzymology.

Direct Activation of Phospholipase C-ϵ by Rho*

T. K. Harden, J. Sondek, M. Wing, 2003, Journal of Biological Chemistry.

Regulation of P2Y1 Receptor-Mediated Signaling by the Ectonucleoside Triphosphate Diphosphohydrolase Isozymes NTPDase1 and NTPDase2

T. K. Harden, J. Boyer, Claudia Alvarado-Castillo, 2005, Molecular Pharmacology.

Turkey erythrocytes possess a membrane-associated inositol 1,4,5-trisphosphate 3-kinase that is activated by Ca2+ in the presence of calmodulin.

T. K. Harden, C. Downes, A. Morris, 1987, The Biochemical journal.

Identification of two benzodiazepine binding sites on cells cultured from rat cerebral cortex.

K. McCarthy, T. K. Harden, T. Harden, 1981, The Journal of pharmacology and experimental therapeutics.

Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.

G. Burnstock, K. Jacobson, G. Dubyak, 2001, Journal of medicinal chemistry.

Requirement of Cys399 for Processing of the Human Ecto-ATPase (NTPDase2) and Its Implications for Determination of the Activities of Splice Variants of the Enzyme*

T. K. Harden, J. Boyer, C. Henry, 2003, Journal of Biological Chemistry.

Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition.

K. Jacobson, T. K. Harden, A. Ivanov, 2009, Bioconjugate chemistry.

Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.

Jacobson, K. Jacobson, Zhang-Guo Gao, 2010, Bioconjugate chemistry.

Differential effects of P2‐purinoceptor antagonists on phospholipase C‐ and adenylyl cyclase‐coupled P2Y‐purinoceptors

K. Jacobson, T. K. Harden, J. Boyer, 1994, British journal of pharmacology.

Agonist and Guanine Nucleotide Regulation of P 2Y Purinergic Receptor-Linked Phospholipase C

T. K. Harden, H. Brown, C. Downes, 1990 .

The Phospholipase C Linked P 2y -Purinergic Receptor

T. K. Harden, H. Brown, A. Morris, 1990 .

Identification of the beta adrenergic receptor subtype on astroglia purified from rat brain.

K. McCarthy, T. K. Harden, T. Harden, 1982, The Journal of pharmacology and experimental therapeutics.

Regulation of inositol trisphosphate accumulation by muscarinic cholinergic and H1-histamine receptors on human astrocytoma cells. Differential induction of desensitization by agonists.

T. K. Harden, N. Nakahata, T. Harden, 1987, The Biochemical journal.

Interaction of beta-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc- S49 lymphoma cells.

P. Molinoff, K. Neve, T. K. Harden, 1988, Biochemical pharmacology.

Dexamethasone increases β-adrenoceptor density in human astrocytoma cells

T. K. Harden, S. J. Foster, T. Harden, 1980 .

Characterization of an altered membrane form of the beta-adrenergic receptor produced during agonist-induced desensitization.

T. K. Harden, J. Perkins, J. Northup, 1983, The Journal of biological chemistry.

Mechanisms of desensitization of β-adrenergic receptors

T. K. Harden, J. Perkins, T. Harden, 1984 .

Isoproterenol-induced desensitization of adenylate cyclase in human astrocytoma cells. Relation of loss of hormonal responsiveness and decrement in beta-adrenergic receptors.

T. K. Harden, J. Perkins, Y. F. Su, 1979, The Journal of biological chemistry.

Role of beta-adrenergic receptors in catecholamine-induced desensitization of adenylate cyclase in human astrocytoma cells.

P. Molinoff, T. K. Harden, G. Johnson, 1978, The Journal of biological chemistry.

[3H]propylbenzilylcholine mustard-labeling of muscarinic cholinergic receptors that selectively couple to phospholipase C or adenylate cyclase in two cultured cell lines.

T. K. Harden, M. Martin, M. Liang, 1987, Molecular pharmacology.

Differential modification of the interaction of cardiac muscarinic cholinergic and beta-adrenergic receptors with a guanine nucleotide binding component(s).

T. K. Harden, A. Scheer, M. Smith, 1982, Molecular pharmacology.

2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists.

K. Jacobson, T. K. Harden, X. Ji, 2003, Journal of medicinal chemistry.

Molecular cloning and characterization of PLC‐η2

T. K. Harden, J. Sondek, M. Wing, 2005 .

CHARACTERIZATION OF THE EFFICACY OF β-ADRENERGIC RECEPTOR AGONISTS IN TERMS OF THE STEADY STATE MODEL FOR THE ACTIVATION OF ADENYLATE CYCLASE

T. K. Harden, J. Perkins, Ying-fu Su, 1979 .

Relationship between an altered membrane form and a low affinity form of the beta-adrenergic receptor occurring during catecholamine-induced desensitization. Evidence for receptor internalization.

T. K. Harden, J. Perkins, M. Toews, 1984, The Journal of biological chemistry.

Catecholamine-induced desensitization involves an uncoupling of beta-adrenergic receptors and adenylate cyclase.

T. K. Harden, J. Perkins, Y. F. Su, 1979, Journal of cyclic nucleotide research.

Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.

K. Jacobson, S. van Calenbergh, T. K. Harden, 2008, Bioorganic & medicinal chemistry.

Selective activation of phospholipase C by recombinant G-protein alpha- and beta gamma-subunits.

T. K. Harden, J. Boyer, J. Garrison, 1994, The Journal of biological chemistry.

Muscarinic cholinergic receptors of two cell lines that regulate cyclic AMP metabolism by different molecular mechanisms.

A. Snowman, T. K. Harden, T. Evans, 1984, Molecular pharmacology.

Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors.

T. K. Harden, A. R. Hughes, M. Martin, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological Selectivities of Molecularly Defined Subtypes of P2Y Receptors

T. K. Harden, E. Lazarowski, J. Boyer, 1998 .

Molecular cloning and expression of an avian G protein-coupled P2Y receptor.

T. K. Harden, J. Boyer, G. L. Waldo, 1997, Molecular pharmacology.

The 6H1 orphan receptor, claimed to be the p2y5 receptor, does not mediate nucleotide-promoted second messenger responses.

T. K. Harden, R. Nicholas, J. Schachter, 1997, Biochemical and biophysical research communications.

Molecular Cloning and Expression of an Avian G Protein-Coupled P 2 Y Receptor

T. K. Harden, J. Boyer, G. L. Waldo, 1997 .

Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.

K. Jacobson, T. K. Harden, S. Costanzi, 2007, Journal of medicinal chemistry.

Induction of Novel Agonist Selectivity for the ADP-Activated P2Y1 Receptor Versus the ADP-Activated P2Y12 and P2Y13 Receptors by Conformational Constraint of an ADP Analog

K. Jacobson, T. K. Harden, J. Boyer, 2004, Journal of Pharmacology and Experimental Therapeutics.

Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.

K. Jacobson, T. K. Harden, B. Joshi, 2004, Biochemical pharmacology.

Identification of competitive antagonists of the P2Y1 receptor.

T. K. Harden, J. Boyer, J. Schachter, 1996, Molecular pharmacology.

Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U‐purinoceptors

W. Watt, T. K. Harden, R. Boucher, 1996 .

Pharmacological selectivity of the cloned human P2U‐purinoceptor: potent activation by diadenosine tetraphosphate

W. Watt, T. K. Harden, R. Boucher, 1995, British journal of pharmacology.

Muscarinic Cholinergic Receptor-Mediated Regulation of Cyclic AMP Metabolism

T. K. Harden, T. Harden, 1989 .

Muscarinic cholinergic receptor-mediated activation of phosphodiesterase.

T. K. Harden, R. Meeker, T. Harden, 1982, Molecular pharmacology.

Pertussis toxin does not inhibit muscarinic-receptor-mediated phosphoinositide hydrolysis or calcium mobilization.

T. K. Harden, S. B. Masters, M. Martin, 1985, The Biochemical journal.

Relationships between phosphoinositide and calcium responses to muscarinic agonists in astrocytoma cells.

T. K. Harden, S. B. Masters, J. Brown, 1984, Molecular pharmacology.

Multiple P2Y receptors mediate contraction in guinea pig mesenteric vein.

T. K. Harden, V. Mutafova-Yambolieva, K. Keef, 2000, General pharmacology.

Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.

G. Burnstock, K. Jacobson, G. Dubyak, 2001, Journal of medicinal chemistry.

Development of an assay for phospholipase C using column-reconstituted, extruded phospholipid vesicles.

T. K. Harden, A. Paterson, C. Myung, 1999, Analytical biochemistry.

Potent and Selective Peptide-based Inhibition of the G Protein G (cid:2) q*

B. Strahl, T. K. Harden, J. Sondek, 2016 .

Galpha12/13- and rho-dependent activation of phospholipase C-epsilon by lysophosphatidic acid and thrombin receptors.

T. K. Harden, M. Wing, D. Siderovski, 2006, Molecular pharmacology.

Molecular cloning and characterization of PLC-eta2.

T. K. Harden, J. Sondek, M. Wing, 2005, The Biochemical journal.

Regulation of cyclic AMP metabolism by muscarinic cholinergic receptors.

T. K. Harden, A. R. Hughes, J. Hepler, 1985, Advances in cyclic nucleotide and protein phosphorylation research.

Dexamethasone increases beta-adrenoceptor density in human astrocytoma cells.

T. K. Harden, S. J. Foster, 1980, Biochemical pharmacology.

Quantification of isozyme-specific activation of phospholipase C-beta2 by Rac GTPases and phospholipase C-epsilon by Rho GTPases in an intact cell assay system.

T. K. Harden, J. Sondek, M. Wing, 2006, Methods in enzymology.

Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats

L. Cubeddu, T. K. Harden, M. Shakarjian, 1984, Clinical pharmacology and therapeutics.

4-Alkyloxyimino Derivatives of Uridine-5′-triphosphate: Distal Modification of Potent Agonists as a Strategy for Molecular Probes of P2Y2, P2Y4, and P2Y6 Receptors

Kenneth A. Jacobson, Kyle A. Brown, T. Kendall Harden, 2014, Journal of medicinal chemistry.

Concentration of enzyme-dependent activation of PLC-β1 and PLC-β2 by Gα11 and βγ-subunits

T. K. Harden, A. Paterson, A. Morris, 1995 .

Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor.

K. Jacobson, T. K. Harden, S. Costanzi, 2008, Combinatorial chemistry & high throughput screening.

Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.

K. Jacobson, T. K. Harden, E. Camaioni, 1998, Journal of medicinal chemistry.

Nucleotides released by apoptotic cells act as a find-me signal for phagocytic clearance

Michael R. Elliott, Marina, Norbert, 2010 .

Kinetic analysis of phospholipase C beta isoforms using phospholipid-detergent mixed micelles. Evidence for interfacial catalysis involving distinct micelle binding and catalytic steps.

T. K. Harden, A. Paterson, C. Downes, 1995, The Journal of biological chemistry.

UDP activates a mucosal-restricted receptor on human nasal epithelial cells that is distinct from the P2Y2 receptor.

W. Watt, T. K. Harden, R. Boucher, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Ser352 and Ser354 in the carboxyl terminus of the human P2Y1 receptor are required for agonist‐promoted phosphorylation and internalization in MDCK cells

T. K. Harden, R. Nicholas, A. Qi, 2011, British journal of pharmacology.

(N)‐methanocarba‐2MeSADP (MRS2365) is a subtype‐specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets

K. Jacobson, T. K. Harden, J. Boyer, 2006, Journal of thrombosis and haemostasis : JTH.

Identification of potent P2Y‐purinoceptor agonists that are derivatives of adenosine 5′‐monophosphate

K. Jacobson, T. K. Harden, S. Siddiqi, 1996, British journal of pharmacology.

Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.

G. Burnstock, K. Jacobson, T. K. Harden, 1993, Journal of medicinal chemistry.

Hormone and growth factor receptor-mediated regulation of phospholipase C activity.

T. K. Harden, J. Hepler, J. Boyer, 1989, Trends in pharmacological sciences.

Purification and functional reconstitution of the human P2Y12 receptor.

T. K. Harden, J. Boyer, E. Bodor, 2003, Molecular pharmacology.

Second messenger cascade specificity and pharmacological selectivity of the human P2Y1‐purinoceptor

T. K. Harden, J. Boyer, R. Nicholas, 1996, British journal of pharmacology.

Potent agonist action of 2‐thioether derivatives of adenine nucleotides at adenylyl cyclase‐linked P2y‐purinoceptors

K. Jacobson, T. K. Harden, B. Fischer, 1995, British journal of pharmacology.

Gi-Dependent Cell Signaling Responses of the Human P2Y14 Receptor in Model Cell Systems

T. K. Harden, E. Lazarowski, R. Carter, 2009, Journal of Pharmacology and Experimental Therapeutics.

Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C

T. K. Harden, J. Boyer, R. Nicholas, 1997, British journal of pharmacology.

Muscarinic cholinergic receptor-mediated attenuation of adenylate cyclase activity in rat heart membranes.

T. K. Harden, M. Smith, 1985, Journal of cyclic nucleotide and protein phosphorylation research.

CHAPTER 225 – The RGS Protein Superfamily

T. K. Harden, D. Siderovski, T. Harden, 2003 .

The UDP-sugar-sensing P2Y(14) receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils.

T. K. Harden, E. Lazarowski, S. Kreda, 2012, American journal of physiology. Cell physiology.

Quantitation of extracellular UTP using a sensitive enzymatic assay

T. K. Harden, E. Lazarowski, T. Harden, 1999, British journal of pharmacology.

Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells.

T. K. Harden, H. Brown, R. Boucher, 1991, Molecular pharmacology.

Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.

K. Jacobson, T. K. Harden, A. Ivanov, 2007, Journal of medicinal chemistry.

Protein Kinase C-Promoted Inhibition of Gα11-Stimulated Phospholipase C-β Activity

T. K. Harden, T. Filtz, M. Cunningham, 1999 .

REGULATION OF PHOSPHOLIPASE C-13 ISOENZYMES

T. K. Harden, A. Paterson, T. Filtz, 1996 .

Regulation of Phospholipase C-β Isoenzymes

T. K. Harden, A. Paterson, T. Filtz, 1996 .

Receptor-induced heterologous desensitization of receptor-regulated phospholipase C.

T. K. Harden, M. Galas, T. Harden, 1995, European journal of pharmacology.

G-protein-mediated regulation of phospholipase C Involvement of βγ subunits.

T. K. Harden, A. Paterson, J. Boyer, 1994, Trends in cardiovascular medicine.

Purification of phospholipase C-activating G protein, G11, from turkey erythrocytes.

T. K. Harden, J. Boyer, G. L. Waldo, 1994, Methods in enzymology.

Purification of G-protein-regulated phospholipase C from turkey erythrocytes.

T. K. Harden, A. Morris, G. L. Waldo, 1994, Methods in enzymology.

G-Protein Regulation of Phospholipase C in the Turkey Erythrocyte

T. K. Harden, A. Morris, J. Boyer, 1993 .

G protein-dependent regulation of phospholipase C by cell surface receptors.

T. K. Harden, T. Harden, 1990, The American review of respiratory disease.

Platelet‐derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells

T. K. Harden, J. Hepler, B. Herman, 1989, Journal of cellular physiology.

Differential Regulation of the Uridine Nucleotide-activated P2Y4 and P2Y6 Receptors

T. K. Harden, A. Brinson, T. Harden, 2001, The Journal of Biological Chemistry.

Molecular cloning, expression and regulatory activity of G alpha 11- and beta gamma-subunit-stimulated phospholipase C-beta from avian erythrocytes.

T. K. Harden, A. Paterson, J. Boyer, 1996, The Biochemical journal.

Is GPR17 a P2Y/Leukotriene Receptor? Examination of Uracil Nucleotides, Nucleotide Sugars, and Cysteinyl Leukotrienes as Agonists of GPR17

T. K. Harden, R. Nicholas, A. Qi, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.

T. K. Harden, J. N. Wells, M. Martin, 1986, Molecular pharmacology.

S. Moro, K. Jacobson, C. Hoffmann, 2001, Farmaco.

Agonist action of adenosine triphosphates at the human P2Y1 receptor.

T. K. Harden, R. K. Palmer, J. Boyer, 1998, Molecular pharmacology.

Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor.

T. K. Harden, R. K. Palmer, R. Nicholas, 1998, Molecular pharmacology.

Signalling and pharmacological properties of the P2Y14 receptor

T. K. Harden, E. Lazarowski, J. Sesma, 2010, Acta physiologica.

Studies of cAMP metabolism in cultured hepatoma cells: Presence of functional adenylate cyclase despite low camp content and lack of hormonal responsiveness

T. K. Harden, J. Wimalasena, B. Leichtling, 1978, Journal of cellular physiology.

Catecholamine-induced alteration in sedimentation behavior of membrane bound beta-adrenergic receptors.

T. K. Harden, C. Cotton, J. Perkins, 1980, Science.

GPR80/99, proposed to be the P2Y15 receptor activated by adenosine and AMP, is not a P2Y receptor

T. K. Harden, R. Nicholas, A. Qi, 2004, Purinergic Signalling.

Lack of nucleotide-promoted second messenger signaling responses in 1321N1 cells expressing the proposed P2Y receptor, p2y7.

T. K. Harden, R. Nicholas, J. Schachter, 1997, Biochemical and biophysical research communications.

Guanine nucleotide regulation of agonist binding to muscarinic cholinergic receptors. Relation to efficacy of agonists for stimulation of phosphoinositide breakdown and Ca2+ mobilization.

T. K. Harden, J. Hepler, S. B. Masters, 1985, The Biochemical journal.

THE USE OF RADIOLABELED LIGANDS TO STUDY β-ADRENERGIC RECEPTORS1

P. Molinoff, T. K. Harden, B. Wolfe, 1976 .

Purification of an AIFT and G-protein @r-Subunit-regulated Phospholipase C-activating Protein*

Boyer, Waldo, T. K. Harden, 2001 .

A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates.

T. K. Harden, S. Delaney, J. Boyer, 2000, Molecular pharmacology.

Protein kinase C inhibits epidermal growth factor-dependent tyrosine phosphorylation of phospholipase C gamma and activation of phosphoinositide hydrolysis.

T. K. Harden, J. Hepler, H. Earp, 1990, Endocrinology.

A membrane-associated, fluorogenic reporter for mammalian phospholipase C isozymes

X. Wang, T. K. Harden, J. Sondek, 2017, The Journal of Biological Chemistry.

Direct activation of purified phospholipase C epsilon by RhoA studied in reconstituted phospholipid vesicles.

T. K. Harden, J. Sondek, Jason P. Seifert, 2006, Methods in enzymology.

The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery

T. K. Harden, D. Erlinge, L. Edvinsson, 2000 .

Characterization of contractile P2 receptors in human coronary arteries by use of the stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate.

T. K. Harden, D. Erlinge, L. Edvinsson, 2000, The Journal of pharmacology and experimental therapeutics.

Pharmacological and second messenger signalling selectivities of cloned P2Y receptors.

W. Watt, T. K. Harden, E. Lazarowski, 1996, Journal of autonomic pharmacology.

Synthesis and structure‐activity relationships of pyridoxal‐6‐arylazo‐5′‐phosphate and phosphonate derivatives as P2 receptor antagonists

G. Burnstock, K. Jacobson, T. K. Harden, 1998, Drug development research.

Further evidence that muscarinic cholinergic receptors of 1321N1 astrocytoma cells couple to a guanine nucleotide regulatory protein that is not Ni.

T. K. Harden, M. Martin, T. Evans, 1985, The Biochemical journal.

G-protein-regulated phospholipase C. Identification of component proteins.

T. K. Harden, 1992, Advances in second messenger and phosphoprotein research.

A receptor and G-protein-regulated polyphosphoinositide-specific phospholipase C from turkey erythrocytes. II. P2Y-purinergic receptor and G-protein-mediated regulation of the purified enzyme reconstituted with turkey erythrocyte ghosts.

T. K. Harden, C. Downes, A. Morris, 1990, The Journal of biological chemistry.

Modification of AlF-4- and receptor-stimulated phospholipase C activity by G-protein beta gamma subunits.

T. K. Harden, C. Downes, J. Northup, 1989, The Journal of biological chemistry.

Identification and purification from bovine brain of a guanine-nucleotide-binding protein distinct from Gs, Gi and Go.

T. K. Harden, J. Northup, M. Martin, 1987, The Biochemical journal.

Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase.

T. K. Harden, T. Harden, 1983, Pharmacological reviews.

C(8) substituted 1-azabicyclo[3.3.1]non-3-enes and C(8) substituted 1-azabicyclo[3.3.1]nonan-4-ones: novel muscarinic receptor antagonists.

T. K. Harden, Chen Wang, H. Kohn, 2003, Journal of medicinal chemistry.

Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon.

T. K. Harden, S. C. Wolff, R. Nicholas, 2005, American journal of physiology. Cell physiology.

Nomenclature and Classification of Purinoceptors*

G Burnstock, B B Fredholm, B. Fredholm, 2005 .

Newly synthesized norepinephrine accumulation in the readily releasable pool of a purified adrenergic vesicle fraction.

T. K. Harden, R. Klein, T. Harden, 1975, Life sciences.

Adrenergic storage vesicles in rat heart: quantitation of membrane-bound and membrane-enclosed dopamine beta-hydroxylase.

P. Molinoff, T. K. Harden, D. Nelson, 1978, The Journal of pharmacology and experimental therapeutics.

Epidermal growth factor stimulates the rapid accumulation of inositol (1,4,5)-trisphosphate and a rise in cytosolic calcium mobilized from intracellular stores in A431 cells.

T. Lovenberg, T. K. Harden, J. Hepler, 1987, The Journal of biological chemistry.

Serum dopamine beta-hydroxylase activity following subarachnoid hemorrhage in man.

T. K. Harden, Å. Thureson-Klein, R. Klein, 1975, Medical biology.

UDP-glucose promotes neutrophil recruitment in the lung

K. Jacobson, T. K. Harden, N. Alexis, 2016, Purinergic Signalling.

The G Protein-Coupled P2Y Receptors

T. K. Harden, T. Harden, 1998 .

Biochemical Properties of a P2Y‐Purinergic Receptor

T. K. Harden, H. Brown, J. Boyer, 1990, Annals of the New York Academy of Sciences.

Towards a revised nomenclature for P1 and P2 receptors.

G Burnstock, B B Fredholm, B. Fredholm, 1997, Trends in pharmacological sciences.

P2-purinergic receptors: subtype-associated signaling responses and structure.

T. K. Harden, J. Boyer, R. Nicholas, 1995, Annual review of pharmacology and toxicology.

Competitive and selective antagonism of P2Y1 receptors by N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphate

K. Jacobson, T. K. Harden, E. Camaioni, 1998, British journal of pharmacology.

Direct Demonstration of Mechanically Induced Release of Cellular UTP and Its Implication for Uridine Nucleotide Receptor Activation*

T. K. Harden, R. Boucher, E. Lazarowski, 1997, The Journal of Biological Chemistry.

A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor.

K. Jacobson, T. K. Harden, A. V. van Rhee, 1997, Molecular pharmacology.